BioLife Solutions Inc
NASDAQ:BLFS
Net Margin
BioLife Solutions Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
BioLife Solutions Inc
NASDAQ:BLFS
|
1.2B USD |
-6%
|
|
| JP |
|
Hoya Corp
TSE:7741
|
6.6T JPY |
23%
|
|
| CH |
|
Alcon AG
SIX:ALC
|
31.7B CHF |
11%
|
|
| DK |
|
Coloplast A/S
CSE:COLO B
|
142.1B DKK |
16%
|
|
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
10.3B USD |
11%
|
|
| CH |
|
Ypsomed Holding AG
SIX:YPSN
|
5.5B CHF |
12%
|
|
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
5B GBP |
9%
|
|
| CN |
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
46.8B CNY |
40%
|
|
| US |
|
Merit Medical Systems Inc
NASDAQ:MMSI
|
5.2B USD |
8%
|
|
| CA |
|
Bausch + Lomb Corp
NYSE:BLCO
|
5.1B USD |
-6%
|
|
| JP |
A
|
Asahi Intecc Co Ltd
TSE:7747
|
716.1B JPY |
9%
|
BioLife Solutions Inc
Glance View
BioLife Solutions Inc., hailing from Bothell, Washington, tells a story of innovation within the niche yet critical biopreservation industry. Emerging as a vital player for cell and gene therapy developers, BioLife Solutions specializes in creating hypothermic storage and transport media tailored for fragile biologic material. Their cornerstone products, like CryoStor and HypoThermosol, are formulated to prolong the shelf-life and viability of cells, tissues, and organs during storage and transportation. These solutions are designed for ultra-cold environments, ensuring the cellular integrity required by biopharmaceutical companies and research institutions engaged in the leading-edge development of regenerative medicine. The company's business model is centered around both direct sales and strategic partnerships. By deeply embedding its proprietary preservation media into clinical-grade processes, BioLife Solutions establishes itself as an integral component of its clients' supply chains. In doing so, the company generates revenue not just from initial sales of its products, but from ongoing usage as therapies move through development pipelines into mainstream clinical applications. Additionally, their diversification into automated thawing devices and personalized medicine services bolster recurring revenue streams, positioning them strategically in an expanding market driven by technological advancements in cellular therapies. Thus, BioLife Solutions stands firmly at the confluence of innovation and necessity, drawing strength from its strategic foresight and commitment to preserving the future of medicine.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on BioLife Solutions Inc's most recent financial statements, the company has Net Margin of -6.1%.
You don't have any saved screeners yet